January 17, 2026

MSFT’s 37% Upside Target & Pharma Leader LLY 01/17/26

2 minutes

Key Stories:

Goldman Sachs is setting a high bar for Microsoft, the software and cloud computing giant, ahead of its January 28th earnings report. The firm has issued a confident ‘buy’ rating with an eye-popping new price target of $655 for Microsoft stock. This aggressive target implies a significant nearly 37% upside from current trading levels, suggesting Goldman Sachs sees considerable growth potential for MSFT in the near to medium term. Investors will be closely watching the upcoming earnings call to see if the company’s performance can justify such bullish analyst sentiment. Read more

Building on that bullish sentiment for Microsoft, it’s clear that analysts are keenly focused on the software giant’s trajectory, particularly with its critical earnings report just around the corner on January 28th. The ‘buy’ rating from Goldman Sachs, reaffirming a strong outlook, underscores the market’s expectation for robust performance, possibly driven by continued strength in its Azure cloud services or advancements in its AI initiatives. This strong analyst endorsement sends a clear signal to investors about the potential for big tech to lead the market, especially those companies with diversified revenue streams and innovation pipelines. Keep an eye on the earnings call for those crucial growth metrics. Read more

Shifting gears now to the healthcare sector, Eli Lilly and Company, the pharmaceutical powerhouse known for its diabetes and obesity treatments, is drawing significant analyst attention. BMO Capital has reaffirmed its ‘Outperform’ rating on Eli Lilly, emphasizing its leadership in the booming obesity market. BMO set a price target of $1,200 for the stock, matching the consensus one-year median target, and implying an upside potential of 16.36%. This analyst endorsement highlights Eli Lilly’s impressive earnings growth trajectory, which is projected to be among the best for the next five years, making it a key stock for growth investors in the pharma space to watch. Read more

Keywords: AI, BMO Capital, Eli Lilly, Goldman Sachs, LLY, MSFT, Microsoft, analyst confidence, analyst report, big tech, buy rating, cloud computing, cloud services, earnings, earnings growth, earnings report, growth metrics, healthcare, obesity market, outperform, pharma, pharmaceutical, price target, software, tech stocks

The post MSFT’s 37% Upside Target & Pharma Leader LLY 01/17/26 first appeared on Rapid Money Radio.

...more